Zobrazeno 1 - 4 of 4 pro vyhledávání: '"EMERALD study group"'
3
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Autor: Bailey, J., Ajana, F., Arribas, J.R., Brunetta, J., Halota, W., Raffi, F., Brinson, C., Eron, J., Post, F., Ward, D., Katlama, C., Pineda, J.A., Rauch, A., Vandercam, B., Molina, J.-M., Slim, J., Crofoot, G., Prelutsky, D., Shamblaw, D., Van Wijngaerden, E., Opsomer, M., Pulido, F., Brown, K., Henn, S., Santos Gil, I., Perez-Valero, I., Flamholc, L., Ruane, P., Ricart, C., De Wit, S., Rey, D., Post, F.A., Murphy, D., Negredo, E., Gatell, J.M., Gathe, J., DeJesus, E., Iribarren, J.A., Rashbaum, B., Fehr, J., Dretler, R., Brar, I., Hagins, D., Voskuhl, G., Jain, M., Henry, W.K., Gasiorowski, J., Mills, A., Rivero, A., Van Landuyt, E., Gutierrez, F., Petrovic, R., Gazzard, B.G., Piekarska, A., Walmsley, S., de Vente, J., Girardy, P.-M., Shafran, S., Rachlis, A., Bhatti, L., Knobel, H., Sogorb, J.P., Cunningham, D., Mounzer, K., Klein, M., Galindo, M.J., Clarke, A., Stoeckle, M., Fichtenbaum, C., Dietz, C., EMERALD study group, Olivet, H., Poizot-Martin, I., Nahass, R., Richmond, G., Eron, J.J., Wilkin, A., Benson, P., Morales-Ramirez, J., Lathouwers, E., Lucasti, C., Moutschen, M., Osiyemi, O., Casado, J., Gallant, J., Jezorwski, J., Teicher, E., Cotte, L., Vandekerckhove, L., Podzamczer, D., Gisslen, M., Gutierrez, M.D.M., Bredeek, U.F., Waters, L., Scribner, A., Orkin, C., Conway, B., Yazdanpanah, Y., Felizarta, F., Reynes, J., Johnson, M.A., Ustianowski, A., Thalme, A., Martorell, C., McDonald, C., Tashima, K., Berenguer, J., Florence, E., Huhn, G., Shalit, P., Ramgopal, M., Witor, A., Blaxhult, A., Scarsella, A., Horban, A., Hufkens, V.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ba763d5fe9b184bc0922e892d7bd0d0
Zobrazit plný text záznamu
4
Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study
Autor: Mandy, Maredza, Hema, Mistry, Noemi, Lois, Steve, Aldington, Norman, Waugh, Victor, Chong
Publikováno v: EMERALD Study Group 2021, ' Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study ', British Journal of Ophthalmology . https://doi.org/10.1136/bjophthalmol-2021-318816
Background/aimsSurveillance of people with previously successfully treated diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) adds pressure on ophthalmology services. This study evaluated a new surveillance pathway entailing m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4e37fd25964de35e3e3aa6503040c36
https://pure.qub.ac.uk/en/publications/surveillance-of-people-with-previously-successfully-treated-diabetic-macular-oedema-and-proliferative-diabetic-retinopathy-by-trained-ophthalmic-graders-cost-analysis-from-the-emerald-study(067f3ed2-fc53-4764-beee-975089ae5827).html
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje